COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose Thromboprophylaxis strategy

As of September 19th, 2020, more than 30 million cases of novel coronavirus disease 2019 (COVID-19), the clinical syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, have been recorded, with more than 900,000 deaths worldwide and 200,000 in the United States, with a case fatality rate exceeding 3% [1].

Source: Thrombosis Research - October 14, 2020 Category: Hematology Authors: Molly M. Daughety, Andrew Morgan, Erin Frost, Chester Kao, Joyce Hwang, Rachel Tobin, Bhavik Patel, Matthew Fuller, Ian Welsby, Thomas L. Ortel Tags: Letter to the Editors-in-Chief Source Type: research